NO.1 PHARMACY released its performance for the first half of the year, with a net profit attributable to the parent company of 14.0242 million yuan, a decrease of 89.19%
NO.1 PHARMACY released its 2025 semi-annual report, with operating revenue of 997 million yuan, a year-on-year increase of 11.58%. The net profit attributable to the parent company was 14.0242 million yuan, a year-on-year decrease of 89.19%. The net profit after deducting non-recurring gains and losses was 9.012 million yuan, a year-on-year increase of 24.58%. The basic earnings per share were 0.0629 yuan. The company achieved operational returns through the expansion of innovative businesses and cost reduction and efficiency improvement
According to the Zhitong Finance APP, NO.1 PHARMACY (600833.SH) released its semi-annual report for 2025, showing an operating income of 997 million yuan, a year-on-year increase of 11.58%. The net profit attributable to shareholders of the listed company was 14.0242 million yuan, a year-on-year decrease of 89.19%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 9.012 million yuan, a year-on-year increase of 24.58%. The basic earnings per share were 0.0629 yuan.
During the reporting period, the year-on-year growth in net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses, as well as the weighted average return on net assets after deducting non-recurring gains and losses, was mainly due to the company's external expansion of innovative businesses and internal efforts to reduce costs and increase efficiency, resulting in operational returns
